Replacing a protease inhibitor (PI) with nevirapine is feasible in HIV infections

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1493, 2005-01, pp. : 18-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nevirapine-based HAART is more effective than protease inhibitor (PI)-based HAART in antiretroviral therapy-naive pregnant women with HIV infection

Inpharma, Vol. 1, Iss. 1590, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Acquisition of Multi-PI (Protease Inhibitor) Resistance in HIV-1 In Vivo and In Vitro

Current Pharmaceutical Design, Vol. 10, Iss. 32, 2004-12 ,pp. : 4055-4064

Bentham Science Publishers

Access to resources Recommend Favorite

Efavirenz- and nevirapine-based HAART equally effective in HIV infections

Inpharma, Vol. 1, Iss. 1379, 2003-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

The Role of Protease Inhibitor Therapy in Children with HIV Infection

By Gavin P.J. Yogev R.

Pediatric Drugs, Vol. 4, Iss. 9, 2002-01 ,pp. : 581-607

Adis International

Access to resources Recommend Favorite

Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment

By Barragan Patricia Podzamczer Daniel

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 13, 2008-09 ,pp. : 2363-2375

Informa Healthcare

Access to resources Recommend Favorite